Introduction
============

Animal models have been used in front-line preclinical studies for predicting efficacy and possible toxicities of anticancer drugs in cancer patients ([@b1-ijo-47-01-0061],[@b2-ijo-47-01-0061]). Current tumor models used for drug evaluation generally consist of implantation into immunodeficient mice of xenografts generated from well-established human cancer cell lines that have already adapted to *in vitro* growth. These models have been used extensively for decades for rapid screening of anticancer drug efficacy ([@b3-ijo-47-01-0061],[@b4-ijo-47-01-0061]).

In recent years, xenografts derived from engrafting fresh surgical specimens directly into immunodeficient mice have enabled the development of more relevant *in vivo* models for human tumors ([@b5-ijo-47-01-0061]). Such patient-derived xenograft (PDX) models, established by direct transfer of tumor tissue, retain similar morphology, architecture, and molecular signatures as the original cancers and thus should be used for rapid screening of potential therapeutics ([@b6-ijo-47-01-0061],[@b7-ijo-47-01-0061]). Whereas the conventional xenograft models using cell lines provide only a monoclonal mass of tumor cells, PDX models recapitulate not only interactions from the host microenvironments but also the cancerous heterogeneity including the cancer stem cells ([@b5-ijo-47-01-0061],[@b6-ijo-47-01-0061],[@b8-ijo-47-01-0061]). Results from these investigations support the use of direct transfer xenografts as a reliable strategy to anticipate clinical findings, provide direction for optimizing personalized treatment in advanced cancers, and suggest novel treatment opportunities in patients with no other therapeutic options ([@b9-ijo-47-01-0061]). The advantages of PDX models in preserving cancer stem cells and the clinical information of the donor patient (so-called 'cancer xenopatient') may allow for accelerated cancer research by simulating the situation in cancer patients more closely ([@b6-ijo-47-01-0061],[@b7-ijo-47-01-0061]).

However, the establishment of direct xenografts is still technically difficult ([@b1-ijo-47-01-0061],[@b10-ijo-47-01-0061],[@b11-ijo-47-01-0061]). Recently, a new immunodeficient animal model, NOD/Shi-scid/IL-2Rγ^null^ (NOG) mice, derived from the NOD/SCID mouse with a common gamma chain, has been introduced. In addition to lacking functional T and B lymphocytes, the NOG mouse has multifunctional defects in natural killer cell activity, macrophage function, complement activity, and dendritic cell function ([@b12-ijo-47-01-0061]). NOG mice were reported to be the most appropriate immunodeficient host animal for direct xenografting of fresh tumor tissue ([@b5-ijo-47-01-0061]).

In the present study, we investigated the efficient establishment of PDX using NOG mice with clinical factors of xenotransplantation. We also discuss herein the application of this newly developed system for not only reliable preclinical studies of new anticancer drugs but also personalized anti-cancer therapies.

Materials and methods
=====================

Tumor tissues for transplantation
---------------------------------

The 116 surgically removed fresh tumor tissues for transplantation were obtained at Kanagawa Cancer Center (Yokohama, Kanagawa, Japan) and Kawasaki Municipal Hospital (Kawasaki, Kanagawa, Japan) with the patients' written informed consent for the study. The study was performed in collaboration with Keihin Coastal Area Life Innovation Comprehensive Special Zones for International Competitiveness Development (Japan) from 2011 to 2012. The ethics committees independently approved the study (authorization number: 176 at Kanagawa Cancer Center, 23--410 at Kawasaki Municipal Hospital). The entire list of engrafted tumors with the patient profiles is shown in [Table I](#tI-ijo-47-01-0061){ref-type="table"}.

Animals
-------

NOG mice, between 6 and 12 weeks of age, were used in this study. The mice were obtained from the Central Institute for Experimental Animals (CIEA; Kanagawa, Japan) ([@b12-ijo-47-01-0061]). All animals were housed in plastic cages (136×208×115 mm) within a vinyl isolator system (1150×500×500 mm) in a pathogen-free state, at a temperature of 22±1°C with 45±10% humidity, and a 12 h light/12 h dark cycle. All experiments involving laboratory animals were performed in accordance with the care and use guidelines of the CIEA, according to our previous studies ([@b13-ijo-47-01-0061]--[@b15-ijo-47-01-0061]). These guidelines meet the generally accepted international criteria on humane treatment that spare the animal needless pain and suffering, and require confirmation that the experiments conducted are of actual scientific benefit to humankind.

Procedures for the establishment of PDX models by serial engraftment
--------------------------------------------------------------------

Fresh tumor tissues were divided into three pieces under sterile conditions. One piece of each tissue specimen was immediately placed in Dulbecco's modified minimal essential medium without antibiotics and without fetal bovine serum, and stored at 4°C until engrafting. Another piece was cryopreserved for molecular biological examination, and the last piece was fixed in 4% formaldehyde for histopathological examination. The piece for engraftment was further divided into small pieces (\~8--64 mm^3^) using sterilized surgical scissors. A small incision was made in the leg of each mouse and a transplant needle was inserted until the tip reached the dorsal subcutaneous area. Approximately 10 pieces of tumor tissue were inoculated into the dorsal subcutis via the needle. After the engrafted mass expanded to over quadruple its size, the xenograft tumor was harvested and directly re-transplanted for expansion in later serial generations using the same procedure. After the tumor tissue had been passaged three times or more and histopathological examination confirmed the PDX to be a growing human tumor, we considered the PDX line as 'established'. The established PDX tissue was divided into small pieces, completely submerged in cryopreservation medium (Cellbanker^®^1, Zenoaq, Fukushima, Japan), and then stored in liquid nitrogen. The frozen tissues were later thawed and used for experiments including re-transplantation and expansion. Mice that did not develop tumor mass over six months after engraftment were sacrificed as 'failed', and this was confirmed histopathologically.

Morphological examination of the primary engrafts and the PDX descendants
-------------------------------------------------------------------------

For morphological analyses, sample tissues were formalin-fixed, paraffin-embedded (FFPE), sliced into 4-μm sections, and subjected to standard hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC). IHC was performed using the Bond Polymer Refine Detection system (Leica Microsystems, Tokyo, Japan) according to the manufacturer's instructions. Nuclei were counterstained with hematoxylin. Primary antibodies used for IHC were: monoclonal anti-HLA class 1-A, B, C (Hokudo, Sapporo, Japan), rabbit polyclonal anti-c-kit (Nichirei Biosciences, Tokyo, Japan); monoclonal anti-CD34, clone NU-4A1 (Nichirei Biosciences); monoclonal antileukocyte common antigen, clone PD7/26, 2B11 (CD111, Nichirei Biosciences); HER2 (Hercep Test™, Dako, Japan), monoclonal anti-estrogen receptor (ER), clone 1D5 (Nichirei Biosciences); and monoclonal antiprogesterone receptor (PgR), clone A9621A (Nichirei Biosciences). Chromogenic *in situ* hybridization (ISH) for Epstein-Barr virus (EBV)-encoded RNA (EBER) was performed using the EBER 1 DNP probe (Ventana/Roche, Tuscon, AZ, USA) and the ISH iView blue plus detection kit (Ventana/Roche) according to the provider's instructions.

Genetic examination of xenograft tumors in NOG mice
---------------------------------------------------

The exon 11 deletion mutation in the *KIT* gene in the 3rd generation xenograft of the gastrointestinal stromal tumor (GIST) was investigated as previously described ([@b16-ijo-47-01-0061]). Briefly, DNA was extracted from the FFPE thin sections of the xenograft tumor and amplified by polymerase chain reaction (PCR) with primers: 5′-gactgagacaataattattaaaag-3′ (forward) and 5′-acccaaaaaggtgacatggaaagc-3′ (reverse). PCR products were then directly sequenced using the PCR primers and the Sanger's method with Genetic Analyzer 3100 (Applied Biosystems/Hitachi, Japan). For EWS-FLI1 fusion mRNA detection, total RNA was extracted from the 3rd generation xenograft of the Ewing sarcoma/primitive neuroectodermal tumor (PNET), reverse transcribed to cDNA, and PCR-amplified with primers: EWS-exon 8 (5′-tcctacagccaagctccaagtc-3′) and the FLI1 exon 9 (5′-gtgatacagctggcgttggc-3′). The obtained product was directly sequenced as described for the *KIT* analysis.

Statistical analysis
--------------------

Statistical comparisons of data sets were performed by a two-sample t-test. The Chi-square test or the two-sided Fisher's probability exact test was applied for comparisons between group frequencies. These analyses were performed using JMP version 11 software (SAS Institute Inc., Cary, NC, USA). P-values of \<0.05 were considered significant.

Results
=======

Efficacy of PDX line establishment in NOG mice
----------------------------------------------

In total, 116 surgically removed tumor tissues were engrafted in NOG mice ([Tables I](#tI-ijo-47-01-0061){ref-type="table"} and [II](#tII-ijo-47-01-0061){ref-type="table"}). The group of patients who provided tumors for this study comprised 63 men and 53 women, with a mean age of 63 years. Thirty-seven tumors were obtained from primary sites and 79 tumors were from metastases. Ninety-eight tumors were epithelial (carcinomas) and 18 tumors were nonepithelial (sarcomas). Tumor specimens were engrafted on the day of surgery or 1--6 days after the surgical removal (owing to sample transport and public holidays). The primary organ site of the transplant together with the difference between the primary tumor or metastasis and the fate (established or failed) are summarized in [Table III](#tIII-ijo-47-01-0061){ref-type="table"}.

PDX lines were considered established when they were passaged three times or more and histopathological examination confirmed their human origin and their morphological similarity to the corresponding engrafted tumor. Of the 116 tumors engrafted, 61 were established as PDX lines, a success rate of 53%. On comparing the established cases with the failed cases, no significant differences were observed in age or gender. The average age of patients in established cases was 64 years, compared with 63 years in the failed cases and there was no statistically significant difference (P=0.53, t-test). In the established cases, 38 cases were from male patients (60%) and 23 were from female patients (43%) cases and there was also no statistically significant difference (P=0.09, Fisher's probability exact test). High establishment rates of PDX lines were observed in tumors of the respiratory system (67%), gastrointestinal tumors (58%), and urological tumors (57%). None of the primary prostatic tumors or brain tumors yielded PDX lines in multiple trials.

The establishment rate among the primary organ sites of engrafts was different; however, there was no statistical significance (P=0.29, Chi-square test). Fifty-eight PDX lines of carcinomas (59%) and three of sarcomas (17%) were established, and the establishment rate was significantly higher for carcinomas (P\<0.001, Fisher's probability exact test). Metastatic tumors yielded PDX lines more effectively than tumors from primary sites (65% and 27%, respectively; P\<0.001, Fisher's probability exact test). Tumors engrafted into NOG mice two or more days after surgical removal showed a higher establishment rate (61%) than those engrafted on the day of surgery or the next day (51%), but there was no statistically significant difference (P=0.49, Fisher's probability exact test).

Preservation of the original tumor characteristics in the PDX of NOG mice
-------------------------------------------------------------------------

The morphological characteristics of the transplanted tumors, as examined by H&E-staining, were well maintained in the corresponding xenograft tumors both cellularly and structurally. One representative case of the PDX line derived from a brain metastasis of an adenosquamous carcinoma of the lung is presented in [Fig. 1](#f1-ijo-47-01-0061){ref-type="fig"}. The primary tumor of the lung consisted of an adenocarcinoma component and a less abundant squamous carcinoma component, and the transitional pattern between them was rare ([Fig. 1A and B](#f1-ijo-47-01-0061){ref-type="fig"}). In contrast, the brain metastasis tumor that was engrafted in NOG mice showed a histological structure of an admixture of adenocarcinoma and squamous carcinoma components, and the tumor characteristics were well preserved in the xenograft tumors through the 1st to the 5th generations ([Fig. 1C and D](#f1-ijo-47-01-0061){ref-type="fig"}). All of the components of the PDX tumor, except for the interstitium, were confirmed as having human origin by IHC for HLA class I ([Fig. 1E](#f1-ijo-47-01-0061){ref-type="fig"}). Similarly, a brain metastasis of a poorly differentiated adenocarcinoma of the lung was established as a PDX tumor of a poorly differentiated adenocarcinoma ([Fig. 1F and G](#f1-ijo-47-01-0061){ref-type="fig"}), whereas a liver metastasis of a moderately differentiated adenocarcinoma of the colon with a cribriform pattern was established as a PDX tumor with a similar histology, indicating that differentiation capacity was generally preserved ([Fig. 1H and I](#f1-ijo-47-01-0061){ref-type="fig"}).

Protein expression, as examined by IHC, was also well maintained in PDX tumors. Only one PDX line was successfully established from 10 trials of GIST engraftment ([Table I](#tI-ijo-47-01-0061){ref-type="table"}). The established line was derived from a recurrent metastasis after imatinib methylate treatment. The 3rd generation xenograft was examined and revealed to be strongly positive for c-kit (a proto-oncogene) and CD34 ([Fig. 2A--D](#f2-ijo-47-01-0061){ref-type="fig"}). A PDX line established from a brain metastasis of a HER2-positive breast cancer showed strong membranous positivity (3^+^) for HER2, and weak dispersed positivity for ER and PgR, and therefore shared the same characteristics as the engrafted tumor ([Fig. 2E--I](#f2-ijo-47-01-0061){ref-type="fig"}).

As expected, genetic alterations were conserved in the PDX tumors of NOG mice. The engrafted GIST tumor contained a 51-nucleotide deletion in exon 11 of *KIT* (r.1667_1717 del/p. Q556_D572 del) and DNA extracted from the 3rd generation xenograft was found to contain an identical mutation ([Fig. 3A](#f3-ijo-47-01-0061){ref-type="fig"}). Furthermore, the Ewing/PNET sarcoma xenograft tumor established from a brain metastasis contained the EWS-FLI1 fusion mRNA just as the original engraft ([Fig. 3B and C](#f3-ijo-47-01-0061){ref-type="fig"}).

Lymphoproliferative lesion (LPL) in NOG mice
--------------------------------------------

In eight cases (7% of all engraftments), transplantable xenograft tumors composed of large monotonous nonepithelial cells were observed whose morphology differed from that of the original tumor ([Fig. 4A](#f4-ijo-47-01-0061){ref-type="fig"}). This phenomenon was observed only in epithelial tumor engraftments ([Tables I](#tI-ijo-47-01-0061){ref-type="table"} and [II](#tII-ijo-47-01-0061){ref-type="table"}). The monotonous cells were HLA class I positive, demonstrating their human origin, and were also positive for leukocyte common antigen (CD111) by IHC and EBER by ISH, indicating the possibility that they were EBV infection-associated LPLs ([Fig. 4B--D](#f4-ijo-47-01-0061){ref-type="fig"}).

Discussion
==========

In this study, we aimed to establish a PDX line in NOG mice that preserved the original characteristics of the engrafted tumor. In a previous PDX trial in NOG mice, which included more than 300 surgically removed tumors, the establishment rate of the xenograft line was 16% (41 of 259 engrafts) for primary tumors, 31% (5 of 16 engrafts) for distant metastasis sites, and 16% (8 of 51 engrafts) for lymph node metastases ([@b5-ijo-47-01-0061]). In this study, we achieved higher establishment rates both for primary tumors (27%) and metastatic tumors (65%). However, the constitution of the tumors used for PDX and those in the primary organ site, the ratios of primary tumors to metastatic tumors, and the numbers of each case all differed between our study and the previous study, making comparisons difficult. For example, the previous study in NOG mice used 57 primary breast cancers and obtained only three PDX lines (5%), whereas primary tumors of the breast were not included in our study ([@b5-ijo-47-01-0061]). In fact, the establishment rate may depend on the organ site from which the engraft is taken.

Colorectal tumors showed relatively higher establishment rates than tumors from other sites in nude or SCID mice ([@b10-ijo-47-01-0061],[@b11-ijo-47-01-0061]); this was also the case in the previous NOG study (17/48 engraftments, 35%) ([@b5-ijo-47-01-0061]). In the present study, establishment rates were found to differ between sites (e.g., 58% for gastrointestinal tumors compared with 14% for urological tumors) but this difference was not statistically significant. The establishment rates of metastatic tumors were significantly higher than those of primary tumors, a finding that was consistent with previous studies ([@b5-ijo-47-01-0061],[@b17-ijo-47-01-0061],[@b18-ijo-47-01-0061]). In our study, carcinomas showed a significantly higher establishment rate (59%) than nonepithelial tumors (17%); however, a limited number of nonepithelial tumors were tested and a larger sample size would be needed to confirm this difference.

In the present study, only subcutaneous transplantations were performed. The transplantation site has been reported to have an influence on xenograft growth ([@b5-ijo-47-01-0061],[@b19-ijo-47-01-0061]--[@b21-ijo-47-01-0061]). Considering what is known about tumor cells and microenvironmental biology, heterotopic subcutaneous tumor models seem to have some shortcomings compared with orthotopic transplantation, especially in the establishment rate and preservation of the original tumor characteristics ([@b21-ijo-47-01-0061]). However, our subcutaneous models revealed well-preserved characteristics of the original engrafts in morphology, protein expression and gene alterations. Although further studies are needed to clarify whether this was because of the highly immunodeficient nature of NOG mice, the establishment of PDX using manageable subcutaneous transplantations is convenient when compared with skillful orthotopic transplantation.

Unexpectedly, in the present study, we experienced no significant difference in the establishment rate of PDX lines between the tumors engrafted early (on the day of surgery or the next day) and the tumors engrafted after 2 days. To the best of our knowledge, no previous studies have investigated this issue. One could speculate that the so-called cancer stem cells responsible for tumorigenicity in mice might be resistance to the severe stress induced by removal from the patients. Although further investigation is needed, this information might help oncology researchers to improve and simplify PDX line establishment, particularly in light of our findings that subcutaneous transplantation is not inferior to orthotopic transplantation with regard to preserving the original engraft characteristics.

The high occurrence of LPL was the most problematic aspect of the establishment of NOG mice-PDX, which arose because of the severely immunodeficient nature of the animal model. In eight cases (7% of all engraftments), the engrafted tumors were replaced by LPL until the 3rd generation of xenografts. The LPLs were demonstrated to be EBV infection-associated, as has been previously reported ([@b20-ijo-47-01-0061],[@b22-ijo-47-01-0061],[@b23-ijo-47-01-0061]). Fujii and colleagues also reported that EBV-infected B cells originating from the donor were distributed systemically within the NOG mouse ([@b23-ijo-47-01-0061]). LPLs were transplantable, and difficult to distinguish from the proper xenografts in terms of gross appearance. It is therefore important that histology of xenografts is checked before transplantation into new mice. However, the frequency of LPLs is acceptable when considering the merits of NOG mice. Replacement of the engrafted tumors by LPL accounted for 15% of the failed cases in PDX line establishment, indicating that the major cause of failed cases is therefore likely to be the nature of the xenografts.

Owing to progression in the field of oncology, the demand for relevant human tumor models is increasing. *In vivo* models play a vital role in the extrapolation of data to human patients, especially in the development of anticancer agents. Evidence that both tumor differentiation and tumor structure were highly conserved between the original surgical specimen and the PDX tumor confirms the suitability of our mouse model for the study of tumor biology. Applications of this model, not only for more common tumors, but also for uncommon tumors, such as sarcomas or pediatric tumors, will provide researchers with reliable comparative preclinical data that may contribute to the development of novel cancer therapies. The rapid and efficient establishment of PDX linking with clinical information may lead in the future to the development of personalized anticancer therapies by simulating various treatments in individual PDX mice, so-called cancer xenopatients.
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![Preserved morphological characteristics observed in the xenograft tumors in NOG mice (A--E) a case of adenosquamous carcinoma of the lung, (F--G) a case of adenocarcinoma of the lung, (H--I) a case of colonic adenocarcinoma. Primary lung carcinoma contained both an adenocarcinoma component (A) and a squamous carcinoma component (B) with few transitional patterns between them. The engrafted brain metastasis showed an admixed histology of adenocarcinoma and squamous carcinoma (C) that was well preserved in the 3rd generation xenograft (D), and immunohistochemically confirmed by the detection of HLA class I (E). The engrafted tumors and the 3rd generation xenograft tumors had similar morphology in NOG PDX lines of a poorly differentiated lung adenocarcinoma (F and G) and a moderately differentiated colonic adenocarcinoma (H and I); Scale bar, 50 μm.](IJO-47-01-0061-g00){#f1-ijo-47-01-0061}

![Preserved protein expression evaluated by IHC in the xenograft tumors in NOG mice (A--D) a case of GIST, (E--I) a case of breast cancer. H&E stained images of the engrafted tumor (A) and the 3rd generation xenograft tumor (B) of the established GIST case are shown. IHC for c-kit (C) and CD34 (D) gave strongly positive signals in the xenograft that reflected those in the engrafted tumor. The 3rd generation xenograft tumor of a HER2 3^+^ breast cancer case showed a similar morphology (F) and similar HER2, ER and PgR IHC patterns (G--I) to the engrafted tumor (E); Scale bar, 50 μm.](IJO-47-01-0061-g01){#f2-ijo-47-01-0061}

![Preserved genetic alterations in the xenograft tumors in NOG mice. (A) Electropherogram of *KIT* exon 11 nucleotide sequencing for the 3rd generation xenograft tumor. A 51-bp deletion (r.1667_1717 del/p. Q556_D572 del) was detected that was identical to the alteration found in the engrafted tumor. (B) Agarose gel image of the reverse-transcription (RT)-PCR product used to amplify the EWS-FLI1 fusion mRNA. RT-PCR of the PBGD gene, a housekeeping gene, was included as a control. (C) Electropherogram of the EWS-FLI1 fusion RT-PCR product.](IJO-47-01-0061-g02){#f3-ijo-47-01-0061}

![Lymphoproliferative lesion observed in the xenograft tumors. (A) A H&E-stained image of monotonous nonepithelial cells in a transplantable xenograft tumor; (B) IHC for HLA class 1; (C) IHC for CD111 (leukocyte common antigen); (D) ISH for EBER; Scale bar, 50 μm.](IJO-47-01-0061-g03){#f4-ijo-47-01-0061}

###### 

The entire list of patients from which the engrafted tumors were taken and the fate of the xenografts.

  No.                                                 Age   Gender   Original tumor site   Pathology                     Primary/Metastasis      Tumor type    Result
  --------------------------------------------------- ----- -------- --------------------- ----------------------------- ----------------------- ------------- ------------------------------------------------------
  1                                                   43    M        Lung                  Adenosquamous carcinoma       Brain metastasis        Epithelial    Established
  2                                                   60    M        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Established
  3                                                   69    M        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  4                                                   35    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  5                                                   51    F        Breast                Ductal carcinoma              Brain metastasis        Epithelial    Established
  6                                                   62    M        Prostate              Adenocarcinoma                Primary                 Epithelial    Failed
  7                                                   65    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  8                                                   76    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  9                                                   60    F        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  10                                                  66    F        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Established
  11                                                  74    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  12                                                  58    M        Nerve                 MPNST                         Primary                 Mesenchymal   Established
  13                                                  28    M        Bone                  Ewing/PNET                    Brain metastasis        Mesenchymal   Established
  14                                                  58    M        Thyroid               Papillary carcinoma           Brain metastasis        Epithelial    Failed
  15                                                  76    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  16                                                  65    F        Breast                Ductal carcinoma              Brain metastasis        Epithelial    Failed
  17                                                  69    F        Large intestine       Tubular adenocarcinoma        Brain metastasis        Epithelial    Established
  18                                                  71    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  19                                                  74    M        Esophagus             Squamous cell carcinoma       Brain metastasis        Epithelial    Established
  20                                                  68    M        Kidney                Renal cell carcinoma          Brain metastasis        Epithelial    Established
  21                                                  81    F        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  22                                                  80    M        Small intestine       GIST                          Primary                 Mesenchymal   Failed
  23                                                  55    M        Prostate              Adenocarcinoma                Primary                 Epithelial    Failed
  24                                                  65    F        Breast                Ductal carcinoma              Brain metastasis        Epithelial    Failed
  25                                                  51    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  26                                                  66    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Failed
  27                                                  40    F        Brain                 Glioblastoma                  Primary                 Mesenchymal   Failed
  28                                                  61    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  29                                                  43    M        Brain                 Glioblastoma                  Primary                 Mesenchymal   Failed
  30                                                  60    M        Stomach               GIST                          Peritoneal metastasis   Mesenchymal   Established
  31                                                  77    M        Stomach               Tubular adenocarcinoma        Peritoneal metastasis   Epithelial    Established
  32                                                  46    M        Brain                 Astrocytoma                   Primary                 Mesenchymal   Failed
  33                                                  61    F        Duodenum              Tubular adenocarcinoma        Primary                 Epithelial    Failed
  34                                                  65    F        Breast                Ductal carcinoma              Brain metastasis        Epithelial    Failed
  35                                                  64    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  36                                                  69    F        Lung                  Squamous cell carcinoma       Brain metastasis        Epithelial    Established
  37                                                  69    F        Uterus body           Adenocarcinoma                Brain metastasis        Epithelial    Established
  38[a](#tfn1-ijo-47-01-0061){ref-type="table-fn"}    58    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  39                                                  70    F        Large intestine       Tubular adenocarcinoma        Brain metastasis        Epithelial    Established
  40                                                  47    M        Primary unknown       Adenocarcinoma                Brain metastasis        Epithelial    Established
  41                                                  71    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  42                                                  71    F        Uterus body           Adenocarcinoma                Brain metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  43                                                  55    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  44                                                  52    M        Lung                  Small cell carcinoma          Brain metastasis        Epithelial    Established
  45                                                  68    M        Prostate              Adenocarcinoma                Primary                 Epithelial    Failed
  46                                                  73    M        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Failed
  47                                                  73    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  48                                                  55    F        Breast                Ductal carcinoma              Brain metastasis        Epithelial    Failed
  49                                                  68    M        Stomach               Tubular adenocarcinoma        Brain metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  50                                                  52    M        Large intestine       GIST                          Primary                 Mesenchymal   Failed
  51                                                  53    F        Nerve                 MPNST                         Primary                 Mesenchymal   Failed
  52                                                  64    M        Large intestine       Tubular adenocarcinoma        Brain metastasis        Epithelial    Failed
  53                                                  62    F        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  54[b](#tfn2-ijo-47-01-0061){ref-type="table-fn"}    70    M        Pancreas              Ductal carcinoma              Lymph node metastasis   Epithelial    Failed
  55[b](#tfn2-ijo-47-01-0061){ref-type="table-fn"}    70    M        Pancreas              Ductal carcinoma              Lymph node metastasis   Epithelial    Established
  56[b](#tfn2-ijo-47-01-0061){ref-type="table-fn"}    70    M        Pancreas              Ductal carcinoma              Lymph node metastasis   Epithelial    Established
  57                                                  35    F        Stomach               GIST                          Primary                 Mesenchymal   Failed
  58                                                  64    M        Lung                  Large cell carcinoma          Brain metastasis        Epithelial    Established
  59                                                  74    F        Pancreas              Anaplastic carcinoma          Primary                 Epithelial    Failed
  60                                                  71    F        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  61                                                  74    F        Pancreas              Ductal carcinoma              Primary                 Epithelial    Failed
  62                                                  70    M        Kidney                Transitional cell carcinoma   Brain metastasis        Epithelial    Failed
  63                                                  53    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed
  64                                                  85    F        Stomach               GIST                          Primary                 Mesenchymal   Failed
  65                                                  67    M        Kidney                Renal cell carcinoma          Brain metastasis        Epithelial    Established
  66                                                  82    M        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Established
  67                                                  61    M        Kidney                Renal cell carcinoma          Peritoneal metastasis   Epithelial    Established
  68                                                  70    F        Stomach               GIST                          Primary                 Mesenchymal   Failed
  69                                                  64    F        Brain                 Glioblastoma                  Primary                 Mesenchymal   Failed
  70                                                  49    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Failed
  71                                                  61    F        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Established
  72                                                  70    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  73                                                  72    F        Large intestine       GIST                          Primary                 Mesenchymal   Failed
  74                                                  69    F        Stomach               GIST                          Primary                 Mesenchymal   Failed
  75                                                  67    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  76                                                  79    M        Brain                 Glioblastoma                  Primary                 Mesenchymal   Failed
  77                                                  60    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  78                                                  63    F        Gallbladder           Pleomorphic carcinoma         Brain metastasis        Epithelial    Failed[c](#tfn3-ijo-47-01-0061){ref-type="table-fn"}
  79                                                  37    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed
  80                                                  70    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  81                                                  68    F        Stomach               GIST                          Primary                 Mesenchymal   Failed
  82                                                  63    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed
  83                                                  70    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed
  84                                                  60    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed
  85                                                  56    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  86                                                  58    F        Breast                Ductal carcinoma              Brain metastasis        Epithelial    Established
  87                                                  16    F        Stomach               GIST                          Primary                 Mesenchymal   Failed
  88                                                  62    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed
  89                                                  71    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  90                                                  65    F        Kidney                Renal cell carcinoma          Skin metastasis         Epithelial    Failed
  91                                                  51    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Failed
  92                                                  51    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Failed
  93                                                  75    M        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Failed
  94                                                  80    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Failed
  95                                                  77    M        Kidney                Renal cell carcinoma          Skin metastasis         Epithelial    Established
  96                                                  68    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  97                                                  63    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Failed
  98                                                  61    F        Pancreas              Ductal carcinoma              Primary                 Epithelial    Failed
  99                                                  67    F        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  100                                                 61    M        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Established
  101                                                 71    M        Stomach               Tubular adenocarcinoma        Brain metastasis        Epithelial    Established
  102[a](#tfn1-ijo-47-01-0061){ref-type="table-fn"}   59    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  103                                                 63    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  104                                                 61    F        Thyroid               Follicular carcinoma          Brain metastasis        Epithelial    Established
  105                                                 71    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  106                                                 46    M        Large intestine       Mucinous adenocarcinoma       Liver metastasis        Epithelial    Established
  107                                                 66    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  108                                                 80    F        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  109                                                 65    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  110                                                 81    F        Thyroid               Anaplastic carcinoma          Primary                 Epithelial    Established
  111                                                 71    M        Pancreas              Ductal carcinoma              Primary                 Epithelial    Established
  112                                                 54    F        Breast                Ductal carcinoma              Brain metastasis        Epithelial    Failed
  113                                                 62    M        Large intestine       Tubular adenocarcinoma        Liver metastasis        Epithelial    Established
  114                                                 68    M        Lung                  Adenocarcinoma                Brain metastasis        Epithelial    Established
  115                                                 63    M        Large intestine       Tubular adenocarcinoma        Brain metastasis        Epithelial    Established
  116                                                 78    M        Kidney                Renal cell carcinoma          Brain metastasis        Epithelial    Failed

Different operations of the same patient,

independent metastatic lesions of the same operation,

replaced by lymphoproliferative lesions, M, male; F, female; MPNST, malignant peripheral nerve sheath tumor; GIST, gastrointestinal stromal tumor.

###### 

Summary of the engrafted tumors and the fate of xenografts.

  Engrafted tumor information   Established   Failed (LPL)   Total                     
  ----------------------------- ------------- -------------- ------- --- -------- ---- ----
  Gastrointestinal                                                                     
   Esophagus                    Epithelial    0              1       0   0        0    1
   Stomach                      Epithelial    0              2       0   1 (1)    0    3
                                Mesenchymal   0              1       6   0        6    1
   Small intestine              Epithelial    0              0       1   0        1    0
                                Mesenchymal   0              0       1   0        1    0
   Large intestine              Epithelial    0              25      0   10 (2)   0    35
                                Mesenchymal   0              0       2   0        2    0
  Other digestive                                                                      
   Pancreas                     Epithelial    8              2       8   1        16   3
   Gallbladder                  Epithelial    0              0       0   1 (1)    0    1
  Respiratory                                                                          
   Lung                         Epithelial    0              10      0   5 (3)    0    15
  Breast and female genital                                                            
   Breast                       Epithelial    0              2       0   5        0    7
   Uterus                       Epithelial    0              1       0   1 (1)    0    2
  Urologic                                                                             
   Kidney                       Epithelial    0              4       0   3        0    7
  Neurologic                                                                           
   Brain                        Mesenchymal   0              0       5   0        5    0
   Nerve                        Mesenchymal   1              0       1   0        2    0
  Others                                                                               
   Bone                         Mesenchymal   0              1       0   0        0    1
   Thyroid                      Epithelial    1              1       0   1        1    2
   Prostate                     Epithelial    0              0       3   0        3    0
   Primary unknown              Epithelial    0              1       0   0        0    1

LPL, lymphoproliferative lesions.

###### 

Comparison of the establishment rate of xenograft lines.

                                                                      Established   Failed   Total   \%   P-value
  ------------------------------------------------------------------- ------------- -------- ------- ---- -------------------------------------------------------
  Original tumor sites                                                                                    0.29[a](#tfn5-ijo-47-01-0061){ref-type="table-fn"}
   Gastrointestinal                                                   29            21       50      58   
   Other digestive                                                    10            10       20      50   
   Respiratory                                                        10            5        15      67   
   Breast and female                                                  3             6        9       33   
   genital                                                                                                
   Urological                                                         4             3        7       57   
   Neurological                                                       1             6        7       14   
   Others                                                             4             4        8       50   
   Total                                                              61            55       116     53   
  Tumor type                                                                                              \<0.001[b](#tfn6-ijo-47-01-0061){ref-type="table-fn"}
   Carcinomas                                                         58            40       98      59   
   Sarcomas                                                           3             15       18      17   
  Tumor site                                                                                              \<0.001[b](#tfn6-ijo-47-01-0061){ref-type="table-fn"}
   Primary                                                            10            27       37      27   
   Metastasis                                                         51            28       79      65   
  Time to engraftment[c](#tfn7-ijo-47-01-0061){ref-type="table-fn"}                                       0.49[b](#tfn6-ijo-47-01-0061){ref-type="table-fn"}
   Early                                                              47            46       93      51   
   Delayed                                                            14            9        23      61   

Chi-square test,

two-sided Fisher's probability exact test,

engraftment on the day of surgery or the next day was considered 'early', and engraftment after 2 days was considered as 'delayed'.
